{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:21:24Z","timestamp":1740144084234,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"grunenthal italia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s40261-021-01074-x","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T10:02:53Z","timestamp":1631700173000},"page":"875-883","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost-Effectiveness Analysis of Tapentadol Versus Oxycodone\/Naloxone in both Branded and Generic Formulations in Patients with Musculoskeletal Pain"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5703-7424","authenticated-orcid":false,"given":"Matteo","family":"Ruggeri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Signorini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Caravaggio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Costanza","family":"Santori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Rosiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flaminia","family":"Coluzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,15]]},"reference":[{"key":"1074_CR1","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.2147\/JPR.S190176","volume":"12","author":"F Coluzzi","year":"2019","unstructured":"Coluzzi F, Polati E, Freo U, Grilli M. Tapentadol: an effective option for the treatment of back pain. J Pain Res. 2019;12:1521\u20138.","journal-title":"J Pain Res"},{"issue":"9","key":"1074_CR2","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1097\/j.pain.0000000000001939","volume":"161","author":"NS Raja","year":"2020","unstructured":"Raja NS, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain. 2020;161(9):1976\u201382.","journal-title":"Pain"},{"issue":"1\u20132","key":"1074_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/s0304-3959(02)00372-x","volume":"102","author":"HSJ Picavet","year":"2003","unstructured":"Picavet HSJ, Shouten JSAG. Musculoskeletal pain in the Netherlands: prevalences, consequences and risk groups, the DMC (3)-study. Pain. 2003;102(1\u20132):167\u201378.","journal-title":"Pain"},{"issue":"2","key":"1074_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4081\/reumatismo.2015.840","volume":"67","author":"S Monti","year":"2015","unstructured":"Monti S, Caporali R. Chronic Pain: the burden of disease and treatment innovation. Reumatismo. 2015;67(2):35\u201344.","journal-title":"Reumatismo"},{"issue":"2","key":"1074_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.berh.2010.01.012","volume":"25","author":"MA Cimmino","year":"2011","unstructured":"Cimmino MA, Ferrone C, Cutolo M. Epidemiology of chronic musculoskeletal pain. Best Pract Res Clin Rheumatol. 2011;25(2):173\u201383.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"9","key":"1074_CR6","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0895-4356(00)00204-3","volume":"53","author":"MA Sprangers","year":"2000","unstructured":"Sprangers MA, de Regt EB, Andries F, et al. Which chronic conditions are associated with better or poorer quality of life? J Clin Epidemiol. 2000;53(9):895\u2013907.","journal-title":"J Clin Epidemiol"},{"key":"1074_CR7","unstructured":"The European Musculoskeletal Conditions Surveillance and Information Network [Internet] Musculoskeletal Health status in Europe v5 2012. http:\/\/www.eumusc.net\/workpackages_wp4.cfm. Accessed 11 Mar 2021"},{"issue":"2","key":"1074_CR8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.berh.2017.10.004","volume":"31","author":"FM Blyth","year":"2017","unstructured":"Blyth FM, Noguchi N. Chronic musculoskeletal pain and its impact on older people. Best Pract Res Clin Rheumatol. 2017;31(2):160\u20138. https:\/\/doi.org\/10.1016\/j.berh.2017.10.004.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"9","key":"1074_CR9","first-page":"1703","volume":"24","author":"KB Hagen","year":"1997","unstructured":"Hagen KB, Kvien TK, Bjorndal A. Musculoskeletal pain and quality of life in patients with noninflammatory joint pain compared to rheumatoid arthritis: a population survey. J Rheumatol. 1997;24(9):1703\u20139.","journal-title":"J Rheumatol"},{"key":"1074_CR10","unstructured":"European Commission. [Internet] Health in the European Union. Special Eurobarometer 272. 2007. http:\/\/ec.europa.eu\/health\/ph_publication\/eb_health_en.pdf. Accessed 15 Jan 2021"},{"issue":"10267","key":"1074_CR11","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/S0140-6736(20)32340-0","volume":"396","author":"A Cieza","year":"2021","unstructured":"Cieza A, Causey K, Kamenov K, Hanson SW, Chatterji S, Vos T. Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2021;396(10267):2006\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(20)32340-0 (Erratum in: Lancet. 2020 Dec).","journal-title":"Lancet"},{"issue":"10","key":"1074_CR12","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.2147\/JPR.S136292","volume":"6","author":"R Del Giorno","year":"2017","unstructured":"Del Giorno R, Frumento P, Varrassi G, Paladini A, Coaccioli S. Assessment of chronic pain and access to pain therapy: a cross-sectional population-based study. J Pain Res. 2017;6(10):2577\u201384.","journal-title":"J Pain Res"},{"issue":"11","key":"1074_CR13","first-page":"859","volume":"72","author":"F Ambrosio","year":"2006","unstructured":"Ambrosio F, Finco G, Mattia C, et al. SIAARTI recommendations for chronic non-cancer pain. Minerva Anestesiol. 2006;72(11):859\u201380.","journal-title":"Minerva Anestesiol"},{"issue":"10137","key":"1074_CR14","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1016\/S0140-6736(18)30480-X","volume":"391","author":"J Hartvigsen","year":"2018","unstructured":"Hartvigsen J, Hancock MJ, Kongsted A, et al. What low back pain is and why we need to pay attention. Lancet. 2018;391(10137):2356\u201367.","journal-title":"Lancet"},{"issue":"10258","key":"1074_CR15","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","unstructured":"GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204\u201322 (Erratum in: Lancet. 2020 Nov 14;396(10262):1562).","journal-title":"Lancet"},{"issue":"5","key":"1074_CR16","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/papr.12308","volume":"16","author":"R Baron","year":"2016","unstructured":"Baron R, Likar R, Martin-Mola E, et al. Effectiveness of tapentadol prolonged release (PR) compared with oxycodone\/naloxone PR for the management of severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, phase 3b\/4 study. Pain Pract. 2016;16(5):580\u201399.","journal-title":"Pain Pract"},{"issue":"11","key":"1074_CR17","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1016\/j.clinthera.2015.08.014","volume":"37","author":"R Buynak","year":"2015","unstructured":"Buynak R, Rappaport AS, et al. Long-term safety and efficacy of tapentadol extended release following up to 2 years of treatment in patients with moderate to severe, chronic pain: results of an open-label extension trial. Clin Ther. 2015;37(11):2420\u201338.","journal-title":"Clin Ther"},{"issue":"1","key":"1074_CR18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1124\/jpet.110.175042","volume":"337","author":"W Schr\u00f6der","year":"2011","unstructured":"Schr\u00f6der W, Tzschentke TM, Terlinden R, et al. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. J Pharmacol Exp Ther. 2011;337(1):312\u201320.","journal-title":"J Pharmacol Exp Ther"},{"key":"1074_CR19","unstructured":"Kent M. The Oxford dictionary of sports science and medicine (3rd ed.). Oxford University Press, Oxford, UK, 2006."},{"issue":"5","key":"1074_CR20","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1080\/14656566.2018.1561863","volume":"20","author":"W Leppert","year":"2019","unstructured":"Leppert W, Zajaczkowska R, Wordliczek J. The role of oxycodone\/naloxone in the management of patients with pain and opioid-induced constipation. Expert Opin Pharmacother. 2019;20(5):511\u201322.","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"1074_CR21","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1185\/03007995.2014.894501","volume":"30","author":"F Coluzzi","year":"2014","unstructured":"Coluzzi F, Ruggeri M. Clinical and economic evaluation of tapentadol extended release and oxycodone\/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain. Curr Med Res Opin. 2014;30(6):1139\u201351.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"1074_CR22","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1517\/14656560902796798","volume":"10","author":"O L\u00f6wenstein","year":"2009","unstructured":"L\u00f6wenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother. 2009;10(4):531\u201343.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1074_CR23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejpain.2008.06.012","volume":"13","author":"W Meissner","year":"2009","unstructured":"Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009;13(1):56\u201364.","journal-title":"Eur J Pain"},{"issue":"4","key":"1074_CR24","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3111\/13696998.2012.670174","volume":"15","author":"R Ikenberg","year":"2012","unstructured":"Ikenberg R, Hertel N, Moore RA, et al. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine. J Med Econ. 2012;15(4):724\u201336.","journal-title":"J Med Econ"},{"issue":"4","key":"1074_CR25","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.clinthera.2012.02.011","volume":"34","author":"M Obradovic","year":"2012","unstructured":"Obradovic M, Ikenberg R, Hertel N, et al. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs. Clin Ther. 2012;34(4):926\u201343.","journal-title":"Clin Ther"},{"key":"1074_CR26","unstructured":"Italian Medicine Agency [Internet] Transparency Lists. https:\/\/www.aifa.gov.it\/liste-di-trasparenza. Accessed 15 Jan 2021."},{"key":"1074_CR27","unstructured":"The Merck Manual Home Edition. Musculoskeletal Pain. Accessed 15 Jan 2021."},{"issue":"3 Suppl","key":"1074_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/eurpub\/13.suppl_1.20","volume":"13","author":"D Bruusgaard","year":"2003","unstructured":"Bruusgaard D. International monitoring of musculoskeletal complaints: a need for consensus. Eur J Public Health. 2003;13(3 Suppl):20\u20133.","journal-title":"Eur J Public Health"},{"issue":"4 Suppl","key":"1074_CR29","first-page":"5","volume":"23","author":"F Marinangeli","year":"2019","unstructured":"Marinangeli F, Evangelista M, Finco G. Tapentadol prolonged release in the treatment of musculoskeletal pain: an innovative pharmacological option. Eur Rev med Pharmacol Sci. 2019;23(4 Suppl):5\u201313.","journal-title":"Eur Rev med Pharmacol Sci"},{"issue":"18","key":"1074_CR30","first-page":"30488","volume":"6736","author":"R Buchbinder","year":"2018","unstructured":"Buchbinder R, van Tulder M, \u00d6berg B, et al. Lancet low back pain series working group. Low back pain: a call for action. Lancet. 2018;6736(18):30488\u201330484.","journal-title":"Lancet"},{"key":"1074_CR31","unstructured":"Kaplan W, Wirtz VJ, Mantel-Teeuwisse A, Stolk P, Duthey B, Laing R. Priority Medicines for Europe and the World: 2013 update. Geneva, Switzerland: World Health Organization; 2013. http:\/\/www.who.int\/medicines\/areas\/priority_medicines\/MasterDocJune28_FINAL_Web.pdf?ua=1. Accessed 17 Jan 2021."},{"issue":"18","key":"1074_CR32","first-page":"30480","volume":"6736","author":"J Hartvigsen","year":"2018","unstructured":"Hartvigsen J, Hancock MJ, Kongsted A, et al. Lancet low back pain series working group. What low back pain is and why we need to pay attention. Lancet. 2018;6736(18):30480.","journal-title":"Lancet"},{"issue":"1","key":"1074_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/j.1532-2149.2012.00170.x","volume":"17","author":"CJ Itz","year":"2013","unstructured":"Itz CJ, Geurts JW, van Kleef M, Nelemans P. Clinical course of non-specific low back pain: a systematic review of prospective cohort studies set in primary care. Eur J Pain. 2013;17(1):5\u201315.","journal-title":"Eur J Pain"},{"key":"1074_CR34","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/j.1533-2500.2010.00397.x","volume":"10","author":"JE Wild","year":"2010","unstructured":"Wild JE, Grond S, Kuperwasser B, et al. Long term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract. 2010;10:416\u201327.","journal-title":"Pain Pract"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01074-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-021-01074-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01074-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T17:05:56Z","timestamp":1632935156000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-021-01074-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,15]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1074"],"URL":"https:\/\/doi.org\/10.1007\/s40261-021-01074-x","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2021,9,15]]},"assertion":[{"value":"8 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was entirely funded by Gr\u00fcnenthal GmbH. The views expressed in this document are those of the authors and do not necessarily correspond to the views of the funders. The study was realized with an unconditional grant by Grunenthal Italia.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"All the authors and contributors to this study\u2014M Ruggeri, A Signorini, S Caravaggio, C Santori, F Rosiello, F Coluzzi,\u2014declare to have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No ethics approval was needed for this study as no clinical patients were involved.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data produced and analyzed in this study are available from the corresponding author upon reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MR, study design and analysis; AS, analysis and writing of the paper; SC, analysis and writing of the paper; SC, part of the analysis; FR, discussion and interpretation of results; FC, discussion and interpretation of results.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Matteo Ruggeri did not receive any funding for the involvement in this study. The views expressed in this paper do not necessarily represent the one of the Istituto Superiore di Sanit\u00e0.","order":11,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}